Blar i NTNU Open på forfatter "Watne, Leiv"

Viser treff 1-7 av 7

    • Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease 

      Henjum, Kristi; Watne, Leiv; Godang, Kristin; Halaas, Nathalie Bodd; Eldholm, Rannveig Sakshaug; Blennow, Kaj; Zetterberg, Henrik; Saltvedt, Ingvild; Bollerslev, Jens; Knapskog, Anne Brita (Journal article; Peer reviewed, 2022)
      Noradrenergic and dopaminergic neurons are involved in cognitive functions, relate to behavioral and psychological symptoms in dementia and are affected in Alzheimer’s disease (AD). Amyloid plaques (A), neurofibrillary ...

    • Cerebrospinal fluid sTREM2 in Alzheimer’s disease: comparisons between clinical presentation and AT classification 

      Knapskog, Anne Brita; Henjum, Kristi; Idland, Ane-Victoria; Eldholm, Rannveig Sakshaug; Persson, Karin Ester Torun; Saltvedt, Ingvild; Watne, Leiv; Engedal, Knut; Nilsson, Lars N.G. (Peer reviewed; Journal article, 2020)
      Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor expressed by microglia. Its cleaved fragments, soluble TREM2 (sTREM2), can be measured in the cerebrospinal fluid (CSF). Previous studies ...

    • A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease 

      Edwin, Trine Holt; Henjum, Kristi; Nilsson, Lars N. G.; Watne, Leiv; Persson, Karin Ester Torun; Eldholm, Rannveig Sakshaug; Saltvedt, Ingvild; Halaas, Nathalie Bodd; Selbæk, Geir; Engedal, Knut; Strand, Bjørn Heine; Knapskog, Anne Brita (Peer reviewed; Journal article, 2020)
      Introduction: The progression rate of Alzheimer's disease (AD) varies and might be affected by the triggering receptor expressed on myeloid cells (TREM2) activity. We explored if cerebrospinal fluid (CSF) soluble TREM2 ...

    • Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease 

      Knapskog, Anne Brita; Aksnes, Mari; Edwin, Trine Holt; Ueland, Per Magne; Ulvik, Arve; Fang, Fei; Eldholm, Rannveig Sakshaug; Halaas, Nathalie Bodd; Saltvedt, Ingvild Tina; Solvang, Stein-Erik Hafstad; Watne, Leiv (Peer reviewed; Journal article, 2023)
      INTRODUCTION The kynurenine pathway's (KP) malfunction is closely related to Alzheimer's disease (AD), for antagonistic kynurenic acid (KA) and agonistic quinolinic acid act on the N-methyl-D-aspartate receptor, a ...

    • Longitudinal trajectories of functional recovery after hip fracture 

      Dakhil, Shams; Saltvedt, Ingvild Tina; Saltyte Benth, Jurate; Thingstad, Anne Pernille Mæhle; Watne, Leiv; Wyller, Torgeir Bruun; Helbostad, Jorunn Hege Lægdheim; Frihagen, Frede; Johnsen, Lars Gunnar; Taraldsen, Kristin (Peer reviewed; Journal article, 2023)
      Background There is limited evidence regarding predictors of functional trajectories after hip fracture. We aimed to identify groups with different trajectories of functional recovery the first year after hip fracture, ...

    • Orthogeriatrics prevents functional decline in hip fracture patients: report from two randomized controlled trials 

      Dakhil, Shams; Thingstad, Pernille; Frihagen, Frede; Johnsen, Lars Gunnar; Lydersen, Stian; Skovlund, Eva; Wyller, Torgeir Bruun; Sletvold, Olav; Saltvedt, Ingvild; Watne, Leiv (Peer reviewed; Journal article, 2021)
      Background The incidence of hip fractures are expected to increase in the following years. Hip fracture patients have in addition to their fracture often complex medical problems, which constitute a substantial burden on ...

    • Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease 

      Aksnes, Mari; Edwin, Trine Holt; Saltvedt, Ingvild Tina; Eldholm, Rannveig Sakshaug; Chaudhry, Farrukh Abbas; Halaas, Nathalie Bodd; Myrstad, Marius; Watne, Leiv; Knapskog, Anne Brita (Peer reviewed; Journal article, 2023)
      Introduction Alzheimer’s disease (AD) can be characterised in vivo by biomarkers reflecting amyloid-β (Aβ) and tau pathology. However, there is a need for biomarkers reflecting additional pathological pathways. Matrix ...